We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Top Pharma, Biotechs and CRO choose ambr250 Automated Mini Bioreactor System

Product News   Apr 25, 2014

 
Top Pharma, Biotechs and CRO choose ambr250 Automated Mini Bioreactor System
FURTHER INFORMATION
 
 
Advertisement
 

Related Product News

IRBM’s Advent Manufactures 13,000 Doses of COVID-19 Vaccine for Use in Phase 2/3 Clinical Trials

Product News

Advent has manufactured 13,000 doses of the novel COVID-19 vaccine candidate, ChAdOx1 nCoV-19 (now known as AZD1222) for use in the Phase 2/3 clinical trial COV002 by the University of Oxford.

READ MORE

Phase I/II Clinical Trial of COVID-19 Vaccine Begins

Product News

Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced enrollment of the first participants in a Phase 1/2 clinical trial of its coronavirus vaccine candidate, NVX‑CoV2373, a stable, prefusion protein made using its proprietary nanoparticle technology.

READ MORE

Ecological Synthesis of Pharmaceutically Relevant Compounds

Product News

Uniqsis reports on how researchers have invested in a FlowLab™ Scale continuous flow reactor to assist them in “green” chemical synthesis of pharmaceutically-relevant compounds.

READ MORE

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE